Abstract
At our institution, Ru-106 plaques have been used in to complement traditional I-125 COMS plaques for radiotherapy management of uveal melanoma. Over 45 patients have been treated with Ru-106 since the launch of this program in late 2003. We report on our experience with treatment planning considerations and quality assurance of Ru-106 beta-emitting plaques.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.